Korean semiconductor equipment stocks surged June 11 as UBS called a WFE supercycle. Samsung and SK Hynix lagged on heavy institutional selling. KOSPI analysis.
KOSPI fell 4.9% on heavy institutional selling while semiconductor equipment names surged. Gigavis hits all five screeners as Korea's top re-rating candidate.
Samsung Biologics, SK Biopharm, Hanmi, Oscotec, Alteogen, ST Pharm. For all six names the 'trigger' that can move the stock is still alive. But 'the catalyst is alive' and 'it's cheap right now' are two completely different statements. Even a great company is a tough new buy if it is already expensive. This is a plain-language follow-up to our earlier bio-sector thesis ('the market rewards stocks where the data is under-priced'), applied to these six names. Bottom line: for fresh money today, SK Biopharm and ST Pharm screen best. Figures are intraday on June 11, 2026 and from company/press sources, so they keep changing.
Samsung Electronics and SK Hynix remain the center of gravity in Korea. But a local screen found 35 Korean companies where FY2026 EPS estimates are up at least 5%, Q1 earnings were positive, and the share price still sits below the 2025 year-end close. This post turns that screen into a Q3 quality watchlist.
KOSPI jumped 7.5% on June 9 as institutions aggressively bought Korean semiconductor stocks after the prior session's circuit breaker. Is it a trend reversal or a dead-cat bounce?
KOSPI triggered a circuit breaker on June 8, 2026, as Korean equities plunged 6.5%. NAVER's AI Factory roadmap was the lone bright spot amid forced deleveraging.
KOSPI hit a circuit breaker (-6.5%) as foreign and institutional selling dominated. 4-screener name Jeju Semiconductor leads quality re-rating candidates.
May 2026 U.S. CPI can print a hot headline because of energy and the low May 2025 base. But the investment event is core CPI MoM. The probability-weighted center is +0.26%, the chance of +0.30% or lower is 75%, and the hot-print tail above +0.35% is 13%.